Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Chronic Prurigo
jRCTs031200073Completed
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dupilumab in chronic prurigo (CPG), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Primary: skin symptom improvement. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
chronic prurigo (CPG)
Beyond the preview
Go deeper on jRCTs031200073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200073.